{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:38:24Z","timestamp":1793353104723,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glycogen storage disease type-Ia patients, deficient in the\n                    <jats:italic>G6PC1<\/jats:italic>\n                    gene encoding glucose-6-phosphatase-\u03b1, lack blood glucose control, resulting in life-threatening hypoglycemia. Here we show our humanized mouse model, huR83C, carrying the pathogenic\n                    <jats:italic>G6PC1<\/jats:italic>\n                    -R83C variant displays the phenotype of glycogen storage disease type-Ia and dies prematurely. We evaluate the efficacy of BEAM-301, a formulation of lipid nanoparticles containing a newly-engineered adenine base editor, to correct the\n                    <jats:italic>G6PC1<\/jats:italic>\n                    -R83C variant in huR83C mice and monitor phenotypic correction through one year. BEAM-301 can correct up to ~60% of the\n                    <jats:italic>G6PC1<\/jats:italic>\n                    -R83C variant in liver cells, restores blood glucose control, improves metabolic abnormalities of the disease, and confers long-term survival to the mice. Interestingly, just ~10% base correction is therapeutic. The durable pharmacological efficacy of base editing in huR83C mice supports the development of BEAM-301 as a potential therapeutic for homozygous and compound heterozygous glycogen storage disease type-Ia patients carrying the\n                    <jats:italic>G6PC1<\/jats:italic>\n                    -R83C variant.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-54108-1","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T23:51:40Z","timestamp":1731196300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia"],"prefix":"10.1038","volume":"15","author":[{"given":"Irina","family":"Arnaoutova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Aratyn-Schaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Dar","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Gregoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Leboeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Boule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-5428","authenticated-orcid":false,"given":"Lo-I","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2453-8633","authenticated-orcid":false,"given":"Genesis","family":"Lung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8655-1476","authenticated-orcid":false,"given":"Thomas","family":"Leete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan S.","family":"Shuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Kothiyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka W.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6497-1605","authenticated-orcid":false,"given":"Jeffrey J.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-6416","authenticated-orcid":false,"given":"Luis","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-7211","authenticated-orcid":false,"given":"Giuseppe","family":"Ciaramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8533-2789","authenticated-orcid":false,"given":"Brian C.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4004-6516","authenticated-orcid":false,"given":"Janice Y.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"key":"54108_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2174\/1566524024605798","volume":"2","author":"JY Chou","year":"2002","unstructured":"Chou, J. Y., Matern, D., Mansfield, B. C. & Chen, Y. T. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr. Mol. Med. 2, 121\u2013143 (2002).","journal-title":"Curr. Mol. Med."},{"key":"54108_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrendo.2010.189","volume":"6","author":"JY Chou","year":"2010","unstructured":"Chou, J. Y., Jun, H. S. & Mansfield, B. C. Glycogen storage disease type I and G6Pase-b deficiency: etiology and therapy. Nat. Rev. Endocrinol. 6, 676\u2013688 (2010).","journal-title":"Nat. Rev. Endocrinol."},{"key":"54108_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10545-014-9772-x","volume":"38","author":"JY Chou","year":"2015","unstructured":"Chou, J. Y., Jun, H. S. & Mansfield, B. C. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase\/glucose-6-phosphate transporter complexes. J. Inherit. Metab. Dis. 38, 511\u2013519 (2015).","journal-title":"J. Inherit. Metab. Dis."},{"key":"54108_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/humu.20772","volume":"29","author":"JY Chou","year":"2008","unstructured":"Chou, J. Y. & Mansfield, B. C. Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum. Mutat. 29, 921\u2013930 (2008).","journal-title":"Hum. Mutat."},{"key":"54108_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJM197602192940805","volume":"294","author":"HL Greene","year":"1976","unstructured":"Greene, H. L., Slonim, A. E., O'Neill, J. A. Jr. & Burr, I. M. Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease. N. Engl. J. Med. 294, 423\u2013425 (1976).","journal-title":"N. Engl. J. Med."},{"key":"54108_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1056\/NEJM198401193100306","volume":"310","author":"YT Chen","year":"1984","unstructured":"Chen, Y. T., Cornblath, M. & Sidbury, J. B. Cornstarch therapy in type I glycogen-storage disease. N. Engl. J. Med. 310, 171\u2013175 (1984).","journal-title":"N. Engl. J. Med."},{"key":"54108_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/advances\/nmz092","volume":"11","author":"KM Ross","year":"2020","unstructured":"Ross, K. M. et al. Dietary management of the glycogen storage diseases: evolution of treatment and ongoing controversies. Adv. Nutr. 11, 439\u2013446 (2020).","journal-title":"Adv. Nutr."},{"key":"54108_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1038\/gim.2014.128","volume":"16","author":"PS Kishnani","year":"2014","unstructured":"Kishnani, P. S. et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet. Med. 16, e1 (2014).","journal-title":"Genet. Med."},{"key":"54108_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/mt.2010.64","volume":"18","author":"WH Yiu","year":"2010","unstructured":"Yiu, W. H. et al. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Mol. Ther. 18, 1076\u20131084 (2010).","journal-title":"Mol. Ther."},{"key":"54108_CR10","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/hep.25717","volume":"56","author":"YM Lee","year":"2012","unstructured":"Lee, Y. M. et al. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 56, 1719\u20131729 (2012).","journal-title":"Hepatology"},{"key":"54108_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ymgme.2017.01.003","volume":"120","author":"GY Kim","year":"2017","unstructured":"Kim, G. Y. et al. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-\u03b1 activity restored are at risk of developing hepatic tumors. Mol. Genet. Metab. 120, 229\u2013234 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"54108_CR12","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/hmg\/ddx097","volume":"26","author":"GY Kim","year":"2017","unstructured":"Kim, G. Y. et al. Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy. Hum. Mol. Genet. 26, 1890\u20131899 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"54108_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/hum.2022.169","volume":"33","author":"AC Nathwani","year":"2022","unstructured":"Nathwani, A. C., McIntosh, J. & Sheridan, R. Liver gene therapy. Hum. Gene Ther. 33, 879\u2013888 (2022).","journal-title":"Hum. Gene Ther."},{"key":"54108_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cels.2022.05.001","volume":"13","author":"P Heinke","year":"2022","unstructured":"Heinke, P. et al. Diploid hepatocytes drive physiological liver renewal in adult humans. Cell Syst. 13, 499\u2013507.e12 (2022).","journal-title":"Cell Syst."},{"key":"54108_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J. & Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381\u2013390 (2009).","journal-title":"J. Infect. Dis."},{"key":"54108_CR16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704\u2013712 (2010).","journal-title":"Hum. Gene Ther."},{"key":"54108_CR17","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.ymthe.2020.12.027","volume":"29","author":"I Arnaoutova","year":"2021","unstructured":"Arnaoutova, I., Zhang, L., Chen, H. D., Mansfield, B. C. & Chou, J. Y. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR\/Cas9-based gene editing. Mol. Ther. 29, 1602\u20131610 (2021).","journal-title":"Mol. Ther."},{"key":"54108_CR18","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/jimd.12660","volume":"46","author":"A Samanta","year":"2023","unstructured":"Samanta, A. et al. CRISPR\/Cas9-based double strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type Ia. J. Inherit. Met. Dis. 46, 1147\u20131158 (2023).","journal-title":"J. Inherit. Met. Dis."},{"key":"54108_CR19","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.dnarep.2008.06.018","volume":"7","author":"Z Mao","year":"2008","unstructured":"Mao, Z., Bozzella, M., Seluanov, A. & Gorbunova, V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair 7, 1765\u20131771 (2008).","journal-title":"DNA Repair"},{"key":"54108_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41580-020-00297-8","volume":"21","author":"B Zhao","year":"2020","unstructured":"Zhao, B., Rothenberg, E., Ramsden, D. A. & Lieber, M. R. The molecular basis and disease relevance of non-homologous DNA end joining. Nat. Rev. Mol. Cell Biol. 21, 765\u2013781 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"54108_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","volume":"154-155","author":"R B\u00f6ttger","year":"2020","unstructured":"B\u00f6ttger, R. et al. Lipid-based nanoparticle technologies for liver targeting. Adv. Drug Deliv. Rev. 154-155, 79\u2013101 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"54108_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-0716-2879-9_12","volume":"2606","author":"D Yang","year":"2023","unstructured":"Yang, D. & Song, C. Q. The delivery of ABE mRNA to the adult murine liver by lipid nanoparticles (LNPs). Methods Mol. Biol. 2606, 159\u2013170 (2023).","journal-title":"Methods Mol. Biol."},{"key":"54108_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/ng0696-203","volume":"13","author":"KJ Lei","year":"1996","unstructured":"Lei, K. J. et al. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type 1a mouse. Nat. Genet. 13, 203\u2013209 (1996).","journal-title":"Nat. Genet."},{"key":"54108_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"54108_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"54108_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","volume":"38","author":"NM Gaudelli","year":"2020","unstructured":"Gaudelli, N. M. et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat. Biotechnol. 38, 892\u2013900 (2020).","journal-title":"Nat. Biotechnol."},{"key":"54108_CR27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR-Cas nucleases, base editors, transposases, and prime editors. Nat. Biotechnol. 38, 824\u2013844 (2020).","journal-title":"Nat. Biotechnol."},{"key":"54108_CR28","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","volume":"29","author":"GA Newby","year":"2021","unstructured":"Newby, G. A. & Liu, D. R. In vivo somatic cell base editing and prime editing. Mol. Ther. 29, 3107\u20133124 (2021).","journal-title":"Mol. Ther."},{"key":"54108_CR29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.ymthe.2022.01.040","volume":"30","author":"MS Packer","year":"2022","unstructured":"Packer, M. S. et al. Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency. Mol. Ther. 30, 1396\u20131406 (2022).","journal-title":"Mol. Ther."},{"key":"54108_CR30","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1074\/jbc.M110486200","volume":"277","author":"J-J Shieh","year":"2002","unstructured":"Shieh, J.-J. et al. The molecular basis of glycogen storage disease type 1a: structure and function analysis of mutations in glucose-6-phosphatase. J. Biol. Chem. 277, 5047\u20135053 (2002).","journal-title":"J. Biol. Chem."},{"key":"54108_CR31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.bbrc.2018.03.083","volume":"498","author":"J-H Cho","year":"2018","unstructured":"Cho, J.-H., Kim, G.-Y., Mansfield, B. C. & Chou, J. Y. Hepatic glucose-6-phosphatase-\u03b1 deficiency leads to metabolic reprogramming in glycogen storage disease type Ia. Biochem. Biophys. Res. Commun. 498, 925\u2013931 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"54108_CR32","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1093\/hmg\/ddv230","volume":"24","author":"G-Y Kim","year":"2015","unstructured":"Kim, G.-Y. et al. Mice expressing reduced levels of hepatic glucose-6-phosphatase-\u03b1 activity do not develop age-related insulin resistance or obesity. Hum. Mol. Genet. 24, 5115\u20135125 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"54108_CR33","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2337\/db11-1300","volume":"61","author":"N Barzilai","year":"2012","unstructured":"Barzilai, N., Huffman, D. M., Muzumdar, R. H. & Bartke, A. The critical role of metabolic pathways in aging. Diabetes 61, 1315\u20131322 (2012).","journal-title":"Diabetes"},{"key":"54108_CR34","doi-asserted-by":"publisher","first-page":"7815","DOI":"10.1007\/s11033-023-08666-0","volume":"50","author":"SS Tamber","year":"2023","unstructured":"Tamber, S. S., Bansal, P., Sharma, S., Singh, R. B. & Sharma, R. Biomarkers of liver diseases. Mol. Biol. Rep. 50, 7815\u20137823 (2023).","journal-title":"Mol. Biol. Rep."},{"key":"54108_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/diagnostics10050297","volume":"10","author":"E Szyma\u0144ska","year":"2020","unstructured":"Szyma\u0144ska, E., Lipi\u0144ski, P., Rokicki, D., Ksi\u0105\u017cyk, J. & Tylki-Szyma\u0144ska, A. Over 20-year follow-up of patients with hepatic glycogen storage diseases: single-Center experience. Diagnostics 10, 297 (2020).","journal-title":"Diagnostics"},{"key":"54108_CR36","first-page":"375","volume":"55","author":"GP Otto","year":"2016","unstructured":"Otto, G. P. et al. Clinical chemistry reference intervals for C57BL\/6J, C57BL\/6N, and C3HeB\/FeJ mice (mus musculus). J. Am. Assoc. Lab. Anim. Sci. 55, 375\u2013386 (2016).","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"54108_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/jat.2550050306","volume":"5","author":"LD Swaim","year":"1985","unstructured":"Swaim, L. D., Taylor, H. W. & Jersey, G. C. The effect of handling techniques on serum ALT activity in mice. J. Appl. Toxicol. 5, 160\u2013162 (1985).","journal-title":"J. Appl. Toxicol."},{"key":"54108_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.omtn.2022.04.012","volume":"28","author":"S Khoja","year":"2022","unstructured":"Khoja, S. et al. Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency. Mol. Ther. Nucleic Acids 28, 859\u2013874 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"54108_CR39","first-page":"23","volume":"18","author":"RD Beegle","year":"2015","unstructured":"Beegle, R. D., Brown, L. M. & Weinstein, D. A. Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I. J. Inherit. Metab. Dis. Rep. 18, 23\u201332 (2015).","journal-title":"J. Inherit. Metab. Dis. Rep."},{"key":"54108_CR40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10545-017-0054-2","volume":"40","author":"GO Okechuku","year":"2017","unstructured":"Okechuku, G. O. et al. Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy. J. Inherit. Metab. Dis. 40, 703\u2013708 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"54108_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/pedi.12540","volume":"18","author":"M Dambska","year":"2017","unstructured":"Dambska, M., Labrador, E. B., Kuo, C. L. & Weinstein, D. A. Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control. Pediatr. Diabetes 18, 327\u2013331 (2017).","journal-title":"Pediatr. Diabetes"},{"key":"54108_CR42","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gt.2014.35","volume":"21","author":"CJ Rocca","year":"2014","unstructured":"Rocca, C. J., Ur, S. N., Harrison, F. & Cherqui, S. rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study. Gene Ther. 21, 618\u2013628 (2014).","journal-title":"Gene Ther."},{"key":"54108_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ymgmr.2015.03.001","volume":"3","author":"YM Lee","year":"2015","unstructured":"Lee, Y. M., Kim, G.-Y., Pan, C.-J., Mansfield, B. C. & Chou, J. Y. Minimal hepatic glucose-6-phosphatase-\u03b1 activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia. Mol. Genet. Metab. Rep. 3, 28\u201332 (2015).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"54108_CR44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.bbrc.2020.04.124","volume":"527","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia. Biochem. Biophys. Res. Commun. 527, 824\u2013830 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"54108_CR45","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/metabo9120282","volume":"9","author":"F Rajas","year":"2019","unstructured":"Rajas, F., Gautier-Stein, A. & Mithieux, G. Glucose-6 phosphate, a central hub for liver carbohydrate metabolism. Metabolites 9, 282 (2019).","journal-title":"Metabolites"},{"key":"54108_CR46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1089\/ten.tec.2014.0152","volume":"21","author":"SS Bale","year":"2015","unstructured":"Bale, S. S. et al. Long-term coculture strategies for primary hepatocytes and liver sinusoidal endothelial cells. Tissue Eng. Part C Methods 21, 413\u2013422 (2015).","journal-title":"Tissue Eng. Part C Methods"},{"key":"54108_CR47","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J.-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"54108_CR48","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"J-P Concordet","year":"2018","unstructured":"Concordet, J.-P. & Haeussler, M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242\u2013W245 (2018).","journal-title":"Nucleic Acids Res."},{"key":"54108_CR49","doi-asserted-by":"publisher","unstructured":"Petri, K. et al. Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects. bioRxiv https:\/\/doi.org\/10.1101\/2021.04.05.438458 (2021).","DOI":"10.1101\/2021.04.05.438458"},{"key":"54108_CR50","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41587-019-0050-1","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim, D., Kim, D.-E., Lee, G., Cho, S.-I. & Kim, J.-S. Genome-wide target specificity of CRISPR RNA-guided adenine base editors. Nat. Biotechnol. 37, 430\u2013435 (2019).","journal-title":"Nat. Biotechnol."},{"key":"54108_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-11-80","volume":"11","author":"JR Dobosy","year":"2011","unstructured":"Dobosy, J. R. et al. RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers. BMC Biotechnol. 11, 80 (2011).","journal-title":"BMC Biotechnol."},{"key":"54108_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0009-8981(88)90256-2","volume":"173","author":"A Burchell","year":"1988","unstructured":"Burchell, A., Hume, R. & Burchell, B. A new microtechnique for the analysis of the human hepatic microsomal glucose-6-phosphatase system. Clin. Chim. Acta 173, 183\u2013191 (1988).","journal-title":"Clin. Chim. Acta"},{"key":"54108_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6336(81)80001-0","volume":"14","author":"HF Teutsch","year":"1981","unstructured":"Teutsch, H. F. Chemomorphology of liver parenchyma. Qualitative histochemical distribution patterns and quantitative sinusoidal profiles of G6Pase, G6PDH and malic enzyme activity and of glycogen content. Prog. Histochem. Cytochem. 14, 1\u201392 (1981).","journal-title":"Prog. Histochem. Cytochem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54108-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T04:03:03Z","timestamp":1731470583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54108-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54108"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54108-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4208786\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,10]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.A.-S., M.S.P., G.C., D.L., S.B., B.B., T.P.F., V.H., J.D., L.-I.C., J.J.Q., L.Y., L.B., L.S.S., C.B., P.K., P.G., K.W.M. and T.L. are employees and shareholders of Beam Therapeutics; G.L. and F.M.G. are shareholders of Beam Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9729"}}